RE:RE:LSDs and Other SpeculationsYeah, I've researched and written about all that stuff for years, prophetoffactz. I'll stick with my cynicism about your LSD comments.
About Fabry, Bioasis's approach is with xB3-004, IL-1Ra, an anti-inflammatory to control Fabry pain. Chiesi/Protalix use an enzyme replacement approach with PRX-102. These are completely different approaches and appear to be complementary. I have written many times about the two approaches. I think you need to do some homework.
I hope Hunter syndrome stays with Bioasis but I am not confident of that. Bioasis needs to decide about its clinical possibilities and plans. RH wouldn't do them, preferring partners to take the xB3 risks. Mark Day and the BoD of which DrDR was chair, stated that they had preclinical/clinical plans. Remember xB3-001 and it PreIND submission to the FDA? And then everything was to be partnered. Now Bioasis is making statements that can be interpreted as plans to go alone into the clinic. Wors like "shelved" are being used. Bioasis is a piblic relations mess. Is that on purpose or is it just ignorance?
About the value of LSDs, calculated current values of enzyme replacement therapies have been dropping in value for years. That's because most of the LSDs are monogenetically caused, leaving them as prime candidates for gene therapy treatment. There may be no better proof of that than the low value of the Chiesi/Bioasis deal for the four LSDs. Because they're secret, investors can't assess the commercial value of the four diseases but at $45 million each, they may represent drops of 60% to 90% in value compared to 5 or 10 years ago. I guess the question would be whether a 20-year patent for an ERT has any value beyond 5 or 10 years because of gene therapies.
Finally, not all LSDs affect the CNS in any way, or in substantial ways. A few years ago Bioasis was saying that there are only a half dozen or so that would be commercially viable enough to bring to the clinic and to market. If Chiesi has four of them, and why would they go for non-commercially viable LSDs, then that may not leave a very big market for Bioasis. That's not to say that there isn't commercial value to LSD ERTs, but after the Chiesi deal, I'm not sure there's enough left to make a monster out of Bioasis. Bioasis, if they're going to promote LSDs, had best make the case for it because it doesn't look great to me.
Rather than just making unsubstantiated statements, prophetoffactz, perhaps you could provide the readers with a list of LSDs that are worth treating with xB3-payloads and what the accumulated value of them might be.
jd